Compare Novo Nordisk A/S (NVO) vs First Trust NASDAQ 100 Technology Index Fund (QTEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs First Trust NASDAQ 100 Technology Index Fund — how do they compare? Novo Nordisk A/S trades at $44.94 (market cap $200.69B), while First Trust NASDAQ 100 Technology Index Fund trades at $310.91. The key difference: Novo Nordisk A/S pays a 3.98% dividend while First Trust NASDAQ 100 Technology Index Fund pays none, and First Trust NASDAQ 100 Technology Index Fund is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| NVO | QTEC | |
|---|---|---|
Market Cap | $200.69B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $63.98 | $335.74 |
52-Week Low | $35.29 | $207.03 |
Enterprise Value | $215.49B | — |
Dividend Yield | 3.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
QTEC trades at $311.57, down 0.22% with neutral technical signals. The ETF shows bearish moving averages but neutral oscillators, with key support at $310 and resistance at $313. Recent coverage highlights its equal-weighted tech exposure and liquidity advantages over peers like RSPT, with software appearing undervalued relative to historical averages according to Seeking Alpha analysis.
The technology sector ETF offers diversified exposure but faces typical sector volatility risks. Current technical positioning suggests limited near-term momentum, while fundamental analysis indicates selective value opportunities within the portfolio components. Market sentiment remains balanced between growth potential and valuation concerns in the tech space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About First Trust NASDAQ 100 Technology Index Fund
QTEC is an ETF that seeks to track the performance of the NASDAQ-100 Technology Sector Index. The fund provides targeted exposure to companies within the NASDAQ-100 that are classified as technology or telecommunications companies, focusing on firms involved in software, hardware, and related services. QTEC is a tool for investors seeking focused exposure to high-growth, large-cap technology companies listed on the NASDAQ exchange.
Read more on QTEC →
